Perlecan is the best-characterized basement membrane heparan sulfate proteoglycan. It has a large (-400 ra>) core protein consisting of five distinct domains. Domain III, a centrally located domain, contains three globular domains separated by cysteine-rich epidermal growth factor (EGF)like repeats. Domain III has overall homology with the N-terminus of the laminin al-chain. The aim of this study was to map a library of nine rat monoclonal antibodies (MAbs) against murine perlecan core protein, using recombinant whole Domain III and defined subdomains of Domain III. ELBA and Western blotting showed that six of the nine MAbs recognized Domain III of perlecan, three of them U. of Alabama at Birmingham, VH 201C, Birmingham, Al35294-0019. mapping to globular Subdomain IIIc, and the other three recognized epitopes within the cysteine-rich regions. All six MAbs stained every basement membrane of several mouse organs as well as some connective tissues, including cartilage. Therefore, several distinct epitopes of perlecan Domain III are present in most if not all basement membranes and are not obscured by intermolecular interactions. These precisely mapped antibodies may therefore be useful in understanding the function of perlecan and its core protein. ( J Histochem Cytochem 43955-%3, 1995) 
Introduction
Proteoglycans (PGs) are ubiquitous components of vertebrate basement membranes, and evidence to date indicates that multiple core proteins may be represented in these specialized extracellular matrices (1) (2) (3) . The best characterized is the large PG perlecan. whose core protein is 396-467 KD in size and is usually substituted with heparan sulfate chains, but in some cases may alternately or additionally bear galactosaminoglycan (GAG) chains (4) (5) (6) and Couchman et al., unpublished experiments) . The control mechanisms underlying glycosylation of this molecule are presently unknown. The core protein is one of the most complex of protein structures identified in extracellular matrices. It consists of five domains, which are described in detail elsewhere (1) (2) (3) . Domain I, at the N-terminus, comprises a short unique sequence, putatively substituted with up to three heparan sulfate chains. Domain I1 has homology with the low-density lipoprotein (LDL) receptor, including the part of the receptor that binds lipoprotein, although whether this is the case with respect to perlecan is not established. Domain 111, the subject of this report, has the highest homology to the N-terminal one third of the laminin al-chain (1) (2) (3) and is composed of three globular domains with alternating cysteine-rich regions, these being epidermal growth factor (EGF)-like repeats. Domain IV consists of a long series of immunoglobulin-like repeats, most closely resembling those of the cell adhesion molecule N-CAM, and it has been proposed that this region may play a role in self-assembly or in cell adhesion (1) . Domain V resembles a portion of laminin, specifically the C-terminal globular region of a-chains (1) (2) (3) , but is also homologous to the C-terminal half of agrin (7) .
Perlecan is not the only basement membrane PG of mammals, other heparan sulfate and chondroitin sulfate PGs also being present (8-10). One of these, BM-CSPG, has a different distribution in some embryonic and adult rat tissues from that of perlecan, being reduced or absent in specific basement membranes during tissue morphogenesis and disease (3, 11, 12) . Perlecan, on the other hand, in addition to being virtually ubiquitous, is expressed very early in development and is also present in some tissue stroma (1-3J3) . The ability of perlecan's heparan sulfate chains to interact with and to potentially stabilize growth factors, such as FGF-2 and TGFP, may be of considerable importance (14.15 ).
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The core protein of perlecan is probably involved in intermolecular interactions between basement membrane components or in adhesion to cells. Perlecan interacts through its core protein with integrin receptors to provide RGD-dependent cell attachment (16J7). Furthermore, Domain 111 of perlecan, expressed as a recombinant protein, functions in cell attachment, which is entirely RGD-dependent (18) . To investigate the distribution and function of perlecan, we previously characterized a number of rat monoclonal antibodies (MAbs) raised against murine perlecan. In this study, we show that six of these MAbs have reactivity with recombinant Domain 111, identlfy the subdomain specificity of each of the six MAbs reacting with Domain 111, and compare their tissue distribution.
Materials and Methods
Antibodies. Nine MAbs recognizing the core protein of whole mouse perlecan have been previously characterized (19) . All have been shown to react with the core protein independent of the GAG moieties. The MAbs are subclass IgGza and were found to react with whole or heparitinasetreated perlecan isolated from the Engelbreth-Holm-Swarm (EHS) tumor matrix. Additional MAbs against entactin and a ubiquitous laminin y1 chain have previously been characterized (20, 21) . Also utilized for control purposes were a polydonal antibody against murine Type IV collagen and two recognizing perlecan, both antigens isolated from the EHS tumor matrix.
Preparation of Recombinant Perlecan Domain III and Its Subdomains.
Construction ofthe cDNA encoding Domain III, its insertion into pRCICMV vector (Invitrogen) and transfection in FIT1080 cells, and the purification of recombinant Domain 111 are described in detail elsewhere (18). In brief, restriction enzymes were used to cut the appropriate regions encoding Domain 111 (amino acid #502-1674 of perlecan) from the overlapping cDNA clones 54, 5, and 72, and then these regions were ligated together. The region of clone 16 encoding perlecan signal peptide was ligated at the 5' end and the stop codon ligated at the 3' end. This cDNA was inserted into the multicloning site of the pRC/CMV vector, the vector transfected into HT1080 cells using lipofectin, and cells were selected for growth in G418. The cloned cell lines were assayed for recombinant Domain III production by SDS-PAGE and Western blotting, using antisera to perlecan. Recombinant Domain I11 was purified from serum-free medium using ammonium sulfate precipitation, followed by chromatography on Superose 6 and Mono Q.
Recombinant proteins for the three globular (cysteine-free) subdomains of Domain 111 were produced as fusion proteins with the maltose-binding protein ofthe pMAL vector (New England Biolabs; Beverly, MA). PCR pdmer pairs for each subdomain were selected by MacVector software. Additional bases were added at the 5' end of the forward primer to create an in-frame EcoRI site with the maltose-binding protein. Bases were also added at the 5' end of the reverse primer to create a stop codon followed by an XbaI site. The primer pair oligos for each domain were used in a Perkin-Elmer thermocycler under standard reaction conditions, using a cDNA to Domain I11 as target DNA. Subdomain IIIa, amino acid #539-721, was generated by the following two primer pairs: 5'-GCGAATXCAGATCCGACEA-GIG-3'. Subdomain IIIb, amino acid #947-1097, was generated by the following two primer pairs: 5'-GCGAAT'KTCGGAACAGCCcTcTcAGT-CCAGCC-3' and 5'-GCTCTAGACTACGGT"KXG'IGTMG~-3'. Subdomain IIIc, amino acid #1329-1490, was generated by the following two primer pain: S -G C G A A T C C G U m -A -The PCR product for each subdomain was cloned into pCRlxript and se-GC'ITIGACC-3' and 5'-GCTCT4GACE4GAEGIGGTATGGACAGTG-XAACCC-Y and 5 ' -G~C G G C A C ' I X T . A C -3 ' . quenced to confirm authenticity. The cDNA for each subdomain was cut out with EcoRI and XbaI and then ligated into the same restriction sites in the pMAL vector. The vector was then used to transform E. coli, the recombinant fusion protein induced with IPTG and subsequently purified by chromatography on an amylose column, all according to the manufacturer's instructions (New England Biolabs).
Preparation of Recombinant Perlecan Domain IIII. Restriction enzymes were used to cut the appropriate regions for the signal peptide, Domain I and Domain 11, from the overlapping cDNA clones 16 and 54, and then these regions were ligated together. A stop codon followed by an XbaI site was added to the 3' end of the construct and a unique NheI site in the signal peptide was changed to a EcoRI site so that the construct could be ligated in frame with the maltose-binding protein in the EcoRIlXbaI sites in the pMAL vector. The recombinant Domains 1/11 were produced as above.
Enzyme-linked Immunosorbent Assay. Antigens, either 250 nglwell recombinant Domain I11 or 10 pglwell ovalbumin. were absorbed from 100 pllwell 10 mM sodium carbonate, 20 mM sodium bicarbonate solution, pH 9.6, overnight at 4'C. After briefwashing, wells were blocked with 1% dried milk in PBS containing 0.02% sodium azide for 2 hr at room temperature (RT). Further washes in PBS containing 0.05% Tween 20 (PBST) were followed by addition of 100 Wllwell primary antibody in PBST. MAbs, as hybridoma supernatants, were diluted 1:8, and polyclonal antibodies were diluted 1:lOOO. Incubation at 37'C was for 1 hr. Prolonged washes in PBST were followed by secondary antibody addition, again 100 pl/well of a 1:2000 dilution in PBST of alkaline phosphatase conjugates of either goat anti-rat IgG (Jackson ImmunoResearch; Avondale, PA) or goat anti-rabbit IgG (Bio-Rad Laboratories; Richmond, CA) for 1 hr at 37'C. Further stringent washes in PBST, then PBS, preceded color development (Bio-Rad) using the manufacturer's recommended methodology. Plates were read at 405 nm.
Western Blotting. Samples of recombinant Domain 111 or its subdomains were resolved by 3-15 % gradient SDS-PAGE, with subsequent transfer to nitrocellulose for immunoblotting. Some samples of whole Domain I11 were digested with V8 protease as previously described (18). Unreduced or reduced samples containing [1] [2] Wgllane protein were sometimes not heat-denatured to maintain epitope conformation suitable for detection by perlecan MAbs. The details of gel electrophoresis and transfer to membranes have been described previously (9).
Membranes were blocked for 0.5-2 hr in 1% or 5% dried milk in PBS or Tris-buffered saline (TBS) containing 0.02% sodium azide (9). When MAbs were used, PBS-containing solutions were used throughout, whereas the higher salt-containing TBS was used for polyclonal antibodies. Primary antibodies were either monoclonal (diluted 1:8) hybridoma supernatants or polyclonal (diluted 1:lOOO) diluted in PBS or TBS containing 1% dried milk, 0.1% bovine serum albumin, 0.1% Tween 20, and 0.02% sodium azide. Incubation was overnight at 4'C or at 37'C for 45 min, followed by 1 hr at RT. Membranes were extensively washed with buffer containing 1% dried milk, then incubated in secondary antibodies for 1 hr at RT diluted 1:2000 in the same buffers as primary antibodies. Secondary antibodies were as indicated for ELISA. Further extensive washing of membranes, with final rinses in protein-and detergent-free buffer, were followed by color development (BioRad) according to the manufacturer's instructions.
Immunofluorescau~ Miamcopy. Frozen sections of mouse tissues (strain B62F1, derived from DBA x C57B1) were prepared from 1-2-month-old mice. These tissues included kidney, skin, liver, ear, skeletal muscle, cornea, and spleen. The tissue sections were treated with undiluted tissue culture supernatants from hybridomas, followed by a tetramethylrhodmine isothiocyanate (TRITC)-conjugated goat anti-rat IgG cross-absorbed with mouse and human serum (Chemicon International; Temecula, CA) as described previously (19.20) . Stained tissue sections were visualized on an Olympus BH-2 fluorescence microscope using an S Plan Apo x 40 objective, Routinely performed specificity controls were negative tibody, together with control antibodies recognizing entactin (ELM1, MAb) or Type IV collagen (polyclonal Ab; Figure 1 ). Of these, six
MAbs and the polyclonal antibody were reactive. and three MAbs (A7L6, C11L1, and A10L4) gave background readings. Control antibodies also gave background activity. Similar rcsults were obtained with Westem blots using whole Domain 111 of perlecan. When Domain 111 samples were unreduced, all six reactive MAbs detected a single polypeptide species of Mr ~1 3 0 KD (Figure 2A ). To test whether the location of the epitope of the PG reactive to an MAb was sensitive to reduction, further Domain 111 samples were reduced with dithioerythritol before Western blot analysis ( Figure 2B ). An apparent increase in molecular mas was noted, consistent with the reduction of intrachain disulfide bonds. Although not quantitative, it was clear that the epitope recognized by the antibody G9L1 was affected by reduction, since reactivity was very weak with the reduced recombinant Domain 111. There was also an apparent reduction in reactivity with MAb BllL1. in contrast to D12L4, which more readily recognized the reduced sample. The other three antibodies showed no change in reactivity ( Figure 2 ).
Subdomain Reactivity of Perlecan Monoclonal Antibodies
All three globular domains from Domain I11 were expressed mombinantly as fusion proteins with maltose-binding protein in bacteria ( Figure 3A) and were tested by Western blot analysis using the six reactive MAbs. Ofthex, three reacted with Domain IIIc (BlU.1, C6L4. and H5L5) ( Figure 3B ), and the other three MAbs failed to react with any of the three globular domains. Therefore, none ofthe six MAbs mognizing whole recombinant Domain 111 reacted with either IIIa or IIIb globular domains. In control lanes, none of the six MAbs recognized either recombinant Domain I or 11. or the maltose-binding protein alone. Two perlecan plyclonal antibodies. on the other hand, recognized all three globular domains of Domain 111. in addition to Domains I and I1 ( Figure 3C ), but not the maltose-binding protein.
From this data, we surmised that the three MAbs not recogniting any of the globular domains were reactive with cysteine-rich regions located between thesc moieties. On the basis of prior knowledge that V8 protease digestion of whole perlecan or whole recom- 
€3 EGFunit Laminin globular unit Figure 4A indicate that whereas antibody G9L1 reacted with the 44 KD fragment only, the other two antibodies, Dl2L4 and DSL5, reacted with an epitope shared by the 44 and 46 KD fragments. In addition, both antibodies reacted with higher I molecular mass, incompletely digested material. The data regarding antibody specificity are summarized in Figure 4B .
In further experiments (not shown), we have ascertained that antibodies A7L6 and C11L1. not reacting with recombinant Domain 111, did not react with either recombinant Domain I or Domain 11.
Immunofluorescence Micro~copy
Comparative staining of several mouse tissues was performed with the MAbs against perlecan core protein, including those reactive with Domain 111. Sections of skin ( Figures SA-5D) show that all antibodies reacted with the dermoepidermal junction, dermal capillaries, and hair follicle basement membranes. Similarly, we could detect no difference in staining of kidney cortex sections ( Figures  5E-5G ). Of particular note was the intense and uniform staining of the glomerular basement membrane by all perlecan-reactive MAbs, regardless of whether or not they were reactive with Domain 111. Control sections stained for laminin yl-chain were also highly reactive ( Figure 5H ).
All six MAbs reactive with perlecan Domain 111 stained the blood vessels and sinusoidal basement membranes of liver ( Figure 6 ). Here, however, one important exception was noted with respect to MAb A10L4. This MAb, not reactive with Domain 111 of perlecan, had the ability to detect bile canaliculi ( Figure 6A ). This MAb was unique in this ability, not shared with antibodies A7L6 and C11L1, which in common with A10L4 do not react with perlecan Domain 111. None of the antibodies reactive with Domain 111 of perlecan stained bile canaliculi ( Figures 6C-6F) .
No difference in staining intensity or distribution was noted in muscle basement membranes ( Figures 7A-7D ) or those of supporting vasculature or neural tissue, and all antibodies reacted strongly with the corneal epithelial and endothelial basement membranes of the eye (Figures 7E-7H ). In addition, we noted staining of the corneal stroma in a discontinuous fibrillar pattern, in keeping with previous observations (6). One other tissue found to be strongly stained with perlecan antibodies, even though basement membranes were not present, was cartilage. Sections of mouse ear ( Figures 8A-8D) showed the presence of perlecan, including Domain 111 in cartilage where the basement membrane components entactin ( Figure 8C ) and laminin (not shown) were not detected. The staining for perlecan was intense within the cartilage matrix. In Figures 8E-8H , staining of the spleen is shown, indicating that perlecan was present in the reticular fibers which are abundant in the red pulp, less abundant in the white pulp, but quite markedly concentrated in the boundary between these two zones. In addition, it was noted that the trabecular smooth muscle was positive for perlecan. As with all other tissues, no difference in pattern of (arrowheads, A-D) . and glomerular basement membranes of the kidney (arrows, F.G). Bar = 50 pm. 
Discussion
Of nine rat MAbs raised against EHS tumor-derived perlecan core protein, six were found to react with whole recombinant perlecan Domain I11 as expressed in a mammalian cell system. We were able to define the site of reactivity more precisely in each case, using a combination of techniques. All three globular subdomains were expressed recombinantly in the pMAL vector as bacterial fusion proteins. Three of the MAbs (BllL1, C6L4, and H5L5) recognized the same subdomain, IIIc, whereas none recognized IIIa or IIIb, although all three domains were recognized by a polyclonal antibody against perlecan. This shows that the bacterial fusion proteins and recombinant proteins expressed in human cells retained their native conformation to a degree that enabled MAbs to bind in Western blotting and ELISA. The data indicate that all three globular domains are antigenic but that there is a possibility that IIIa and IIIb are highly conserved between mouse and rat and do not elicit an immune response. In contrast, antibodies are readily produced against Domain IIIc. It can be predicted that the epitope recognized by BllLl is distinct from the other two, based on sensitivity to reduction of whole Domain 111 in immunoblots (Figure 2) .
Utilizing the knowledge that the proteinase V8 will cleave perlecan, or its constituent Domain 111, to yield protease-resistant fragments of 44 KD and 46 KD (18.22) . we prepared these fragments of recombinant whole Domain 111 and tested them by immunoblotting for reactivity with the MAbs. These protease-resistant fragments represent a portion of the EGFlike repeats between Domains IIIa and IIIb ( Figure 4B ). The identical digestion products of V8 cleavage of native whole perlecan and its recombinant Domain 111 also show that native conformation of the domain expressed in mammalian cells is retained. A further three antibodies were mapped to these cysteine-rich structures, one uniquely to the 44 KD fragment (GyLl), the other two apparently recognizing shared epitopes found in these two subdomains. Consequently, these two antibodies (D5L5, D12L4) were able to detect both the 44 and 46 KLI fragments in immunoblots. It is perhaps worth pointing out that the precise epitope recognized by G9L1 could be predicted to be different from that recognized by the other two antibodies, since G9L1 reactivity to whole recombinant Domain 111 was sensitive to reduction. It is also likely that D12L4 and D5L5 recognize distinct epitopes within these subdomains, since reactivity of the former, but not the latter, in immunoblots of whole recombinant Domain 111 was enhanced by reduction (Figure 2) .
On the whole, it appears that Domain I11 is very antigenic, perhaps in common with laminin, which also has this property. Although Domain I11 of perlecan has homology with laminin short arms (1) (2) (3) 23, 24) , none of the antibodies against perlecan reacts with laminin. or vice versa (19) . Staining of frozen sections of skin, cartilare. kidnev. cornea. muscle. and liver indicates that all six an-" , I , antibodies recognizing Domains IV or v give different staining patterns. While A7L6 is similar to Domain 111 antibodies, A10L4 additionally stains bile canaliculi (arrows, A). Bar = 50 pm. tibodies recognizing Domain 111 epitopes have identical tissue staining patterns. In each case, all basement membranes are readily stained, in keeping with distribution seen previously with these and many other antibodies (3,4,19.25,26) . One previous study with a single MAb against Domain I11 of perlecan also appeared to de-I I I 961 tect perlecan in all human basement membranes examined. together with some selective stromal staining (13). In no case did we find that the epitope recognized by any single MAb was partially or totally obscured or absent from a particular tissue. Our tentative conclusions are that either these subdomains are not involved in intermolecular interactions between basement membrane components or between perlecan and cell surface receptors, or that only a small proportion of the perlecan subdomains are occupied in this manner. Overall, multiple subdomains from perlecan Domain I11 are readily detectable under all these circumstances, and in all tissues and their basement membranes. Three other points are perhaps worthy of mention in this regard. Previous efforts to isolate intact perlecan core protein from kidney glomerular basement membranes have met with little success, although large fragments of approximate Mr 200-300 K have been identified (26). Our work, in keeping with a previous study (13), indicates that Domain 111 of perlecan is clearly present in this highly specialized basement membrane. Because one brief report (27) has indicated the presence of both the N-and C-terminal domains of perlecan in this structure, using antibodies against synthetic peptides, we conclude that perlecan either is readily cleaved in the process of purification or is perhaps cleaved in situ, as suggested previously (28).
Second, perlecan was readily detected in hyaline cartilage, in contrast to other basement membrane components, such as entactin and laminin. This would indicate that basement membrane PG is present in the cartilage matrix, an interesting finding whose functional significance is unknown. The structure of cartilage perlecan is presently under investigation by one of us (JRH). Third, it has previously been reported that perlecan synthesized by corneal keratocytes is a chondroitin sulfate-substituted variant of perlecan (6). The precise sites of chondroitin sulfate substitution on the core protein have not yet been established, but we confirm that perlecan Domain I11 is readily detectable in the corneal stroma, in addition to its presence in the corneal epithelial and endothelial basement membranes.
Three of the MAbs react with a domain other than 111. We have also determined that they d o not react with Domains I or 11, indicating their reactivity either with domains IV or V. One of these antibodies, A10L4, has a unique tissue distribution, in that it stained the bile canaliculi of mouse liver. This pattern of staining was not shared by any of the other MAbs, including all those recognizing Domain 111, whose distribution is limited to the blood vessels and sinusoidal regions of liver, where there is a discontinuous distribution of basement membrane in the space of Disse (8.13). The precise nature of the perlecan distributed in bile canaliculi will be of interest, because it appears that Domain 111 of perlecan is either absent or is totally obscured in such a way that all six of our MAbs cannot detect it in tissue sections. Our preliminary data (Couch- man, unpublished results) suggest that A10L4 recognizes recombinant Domain V of perlecan, whereas A7L6 and CllLl did not, implying that they have reactivity with Domain IV of perlecan core protein.
It has previously been reported that murine but not human perlecan Domain IIIa contains an Arg-Gly-Asp motif(RGD). This motif is present in many extracellular matrix molecules and is in some instances involved in interaction with cell surface integrin receptors (29). It is interesting that this subdomain, along with IIIb, did not react with any of the MAbs. It is possible that this region of perlecan is active in cell adhesion but that none of the MAbs we have characterized will interfere with this activity, especially because rotary shadowing data indicate that Domains IIIa, b, and c represent spatially distinct, separate globules (1).
In conclusion, we have mapped six MAbs to subdomains of Domain 111 of perlecan, one of the largest domains found in this basement membrane and connective tissue proteoglycan. These reagents, although reacting with different regions of the perlecan domain, all share the same capacity to react with perlecan in situ, indicating that this domain of perlecan is readily accessible. If this domain is involved in intermolecular interactions, it appears therefore that they occur in such a way as not to obscure any Domain I11 epitopes that we can detect. , (B,G) D5L5, (D) CllLl, (E) H5L5, (F) A7L6, and (H) G9L1, against perlecan core protein. An entactin-specific antibody (ELM 1) was used in C. In addition to muscle, peripheral nerve, blood vessel and dermo-epidermal junction staining, perlecan, but not entactin, was present within the cartilage matrix (C). The reticular meshwork of spleen is rich in perlecan. particularly where it is concentrated at the boundary between white and red pulp (arrowheads, F). Blood vessels and trabeculae (arrows. E) are also well stained. Bar = 50 wm.
